These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 27764560)

  • 1. Ebola vaccines in clinical trial: The promising candidates.
    Wang Y; Li J; Hu Y; Liang Q; Wei M; Zhu F
    Hum Vaccin Immunother; 2017 Jan; 13(1):153-168. PubMed ID: 27764560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ebola vaccine trials: progress in vaccine safety and immunogenicity.
    Matz KM; Marzi A; Feldmann H
    Expert Rev Vaccines; 2019 Dec; 18(12):1229-1242. PubMed ID: 31779496
    [No Abstract]   [Full Text] [Related]  

  • 3. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.
    Huttner A; Dayer JA; Yerly S; Combescure C; Auderset F; Desmeules J; Eickmann M; Finckh A; Goncalves AR; Hooper JW; Kaya G; Krähling V; Kwilas S; Lemaître B; Matthey A; Silvera P; Becker S; Fast PE; Moorthy V; Kieny MP; Kaiser L; Siegrist CA;
    Lancet Infect Dis; 2015 Oct; 15(10):1156-1166. PubMed ID: 26248510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ebola vaccines - Where are we?
    Watle SV; Norheim G; Røttingen JA
    Hum Vaccin Immunother; 2016 Oct; 12(10):2700-2703. PubMed ID: 27548643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization.
    Dahlke C; Kasonta R; Lunemann S; Krähling V; Zinser ME; Biedenkopf N; Fehling SK; Ly ML; Rechtien A; Stubbe HC; Olearo F; Borregaard S; Jambrecina A; Stahl F; Strecker T; Eickmann M; Lütgehetmann M; Spohn M; Schmiedel S; Lohse AW; Becker S; Addo MM;
    EBioMedicine; 2017 May; 19():107-118. PubMed ID: 28434944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in the development of vaccines for Ebola virus disease.
    Ohimain EI
    Virus Res; 2016 Jan; 211():174-85. PubMed ID: 26596227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Vesicular Stomatitis Virus-Ebola Virus Postexposure Treatment in Rhesus Macaques Infected With Ebola Virus Makona.
    Marzi A; Hanley PW; Haddock E; Martellaro C; Kobinger G; Feldmann H
    J Infect Dis; 2016 Oct; 214(suppl 3):S360-S366. PubMed ID: 27496978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant vesicular stomatitis virus expressing Ebola virus glycoprotein (rVSV-EBOV), a new Ebola vaccine.
    Kasereka MC; Mumtaz Z; Hawkes MT
    Drugs Today (Barc); 2021 Jan; 57(1):27-45. PubMed ID: 33594388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ebola Virus: Pathogenesis and Countermeasure Development.
    Furuyama W; Marzi A
    Annu Rev Virol; 2019 Sep; 6(1):435-458. PubMed ID: 31567063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials.
    Suder E; Furuyama W; Feldmann H; Marzi A; de Wit E
    Hum Vaccin Immunother; 2018; 14(9):2107-2113. PubMed ID: 29757706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe.
    Agnandji ST; Huttner A; Zinser ME; Njuguna P; Dahlke C; Fernandes JF; Yerly S; Dayer JA; Kraehling V; Kasonta R; Adegnika AA; Altfeld M; Auderset F; Bache EB; Biedenkopf N; Borregaard S; Brosnahan JS; Burrow R; Combescure C; Desmeules J; Eickmann M; Fehling SK; Finckh A; Goncalves AR; Grobusch MP; Hooper J; Jambrecina A; Kabwende AL; Kaya G; Kimani D; Lell B; Lemaître B; Lohse AW; Massinga-Loembe M; Matthey A; Mordmüller B; Nolting A; Ogwang C; Ramharter M; Schmidt-Chanasit J; Schmiedel S; Silvera P; Stahl FR; Staines HM; Strecker T; Stubbe HC; Tsofa B; Zaki S; Fast P; Moorthy V; Kaiser L; Krishna S; Becker S; Kieny MP; Bejon P; Kremsner PG; Addo MM; Siegrist CA
    N Engl J Med; 2016 Apr; 374(17):1647-60. PubMed ID: 25830326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.
    Mire CE; Matassov D; Geisbert JB; Latham TE; Agans KN; Xu R; Ota-Setlik A; Egan MA; Fenton KA; Clarke DK; Eldridge JH; Geisbert TW
    Nature; 2015 Apr; 520(7549):688-691. PubMed ID: 25853476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus.
    Dhama K; Karthik K; Khandia R; Chakraborty S; Munjal A; Latheef SK; Kumar D; Ramakrishnan MA; Malik YS; Singh R; Malik SVS; Singh RK; Chaicumpa W
    Front Immunol; 2018; 9():1803. PubMed ID: 30147687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Recent Advances in Vaccines and Drugs Against the Ebola Virus].
    Zhu X; Yao C; Wei Y; Kou Z; Hu K
    Bing Du Xue Bao; 2015 May; 31(3):287-92. PubMed ID: 26470536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial.
    ElSherif MS; Brown C; MacKinnon-Cameron D; Li L; Racine T; Alimonti J; Rudge TL; Sabourin C; Silvera P; Hooper JW; Kwilas SA; Kilgore N; Badorrek C; Ramsey WJ; Heppner DG; Kemp T; Monath TP; Nowak T; McNeil SA; Langley JM; Halperin SA;
    CMAJ; 2017 Jun; 189(24):E819-E827. PubMed ID: 28630358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic.
    Coller BG; Blue J; Das R; Dubey S; Finelli L; Gupta S; Helmond F; Grant-Klein RJ; Liu K; Simon J; Troth S; VanRheenen S; Waterbury J; Wivel A; Wolf J; Heppner DG; Kemp T; Nichols R; Monath TP
    Vaccine; 2017 Aug; 35(35 Pt A):4465-4469. PubMed ID: 28647166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ebola: Lessons on Vaccine Development.
    Feldmann H; Feldmann F; Marzi A
    Annu Rev Microbiol; 2018 Sep; 72():423-446. PubMed ID: 30200851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV.
    Ehrhardt SA; Zehner M; Krähling V; Cohen-Dvashi H; Kreer C; Elad N; Gruell H; Ercanoglu MS; Schommers P; Gieselmann L; Eggeling R; Dahlke C; Wolf T; Pfeifer N; Addo MM; Diskin R; Becker S; Klein F
    Nat Med; 2019 Oct; 25(10):1589-1600. PubMed ID: 31591605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic changes of circulating miRNAs induced by the Ebola virus vaccine VSV-EBOV.
    Fischer T; Spohn M; Olearo F; Zinser ME; Kasonta R; Stubbe HC; Rechtien A; Ly ML; Schmiedel S; Lohse AW; Grundhoff A; ; Addo MM; Dahlke C
    Vaccine; 2018 Nov; 36(46):7083-7094. PubMed ID: 30244872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ebola virus disease candidate vaccines under evaluation in clinical trials.
    Martins KA; Jahrling PB; Bavari S; Kuhn JH
    Expert Rev Vaccines; 2016 Sep; 15(9):1101-12. PubMed ID: 27160784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.